BELLUS Health is a biopharmaceutical company focused on developing treatments for refractory chronic cough and other cough hypersensitivity conditions. Their lead product candidate, BLU-5937, is currently in Phase II clinical trials for the treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.